



Forfivo XL[®] (bupropion) – First-time generic

- On September 27, 2018, Alvogen and Wockhardt launched authorized generic versions of Almatica Pharma's [Forfivo XL \(bupropion\)](#) extended-release tablets.
- Forfivo XL is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual.
- Bupropion is also available generically as an immediate-release [tablet](#) and generic versions of several other extended-release formulations ([Wellbutrin SR[®]](#), [Wellbutrin XL[®]](#), and [Zyban[®]](#)). In addition, extended-release bupropion is available as the branded product [Aplenzin[®]](#).
 - Immediate-release bupropion and extended-release Wellbutrin SR are indicated for MDD.
 - In addition to MDD, other extended-release formulations of bupropion (ie, Aplenzin, Wellbutrin XL) are also approved for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder.
 - Zyban is only indicated as an aid to smoking cessation treatment.
- Forfivo XL carries a boxed warning for suicidal thoughts and behaviors.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.